Companies
Beckley Psytech
its BPL-003 intranasal 5-MeO-DMT formulation reported positive Phase IIa topline data in May 2025 showing durable efficacy up to three months in treatment-resistant depression from a single dose, with a session substantially shorter than a multi-hour psilocybin trip;…
- Country
- United Kingdom
intranasal
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Psychedelic medicine & neuropsychiatric biologics | therapeutics-platforms | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.